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Objective: Purposes of the present study were to assess the social cognitive impairment in schizophrenia and to detect if 
some clinical variables (particularly age at onset) are predictive of general/social cognitive deficit in schizophrenia patients. 
Method: Thirty-five clinically stabilized schizophrenia outpatients were assessed by the Brief Assessment of Cognition in 
Schizophrenia (BACS) and by Torralva’s social cognition battery. Binary logistic models were performed to find an eventual 
association between continuous clinical variables and cognitive test failures. The total sample was divided in groups 
according to dichotomous variables (gender, diagnostic subtypes and type of abuse) and the presence of cognitive deficits 
was compared between groups by χ2 tests. 
Results: An earlier age at onset was found to be predictive of frontal cognitive impairment (Tower of London p=0.038, 
OR=0.702). Female gender was more probably associated with mistakes at MET-HV (χ2= 4.80, p=0.05, phi=0.40) and 
HOTEL tests (χ2= 5.25, p=0.04, phi=0.4) than male one. Cannabis abusers showed more frequently deficits on verbal 
fluency (χ2= 9.35, p=0.04, phi=0.52) and executive functioning (Tower of London) (χ2= 11.67, p=0.02, phi=0.58) than 
alcohol/cocaine ones. 
Conclusion: Female patients with an early age at onset and cannabis abuse seem to have the worst general and social 
cognitive profile among patients suffering from schizophrenia. 
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Several studies have shown that global cognitive 
impairment and deficits in the processing of emotions 
are typical features of schizophrenia (1-6). 
Schizophrenia patients appear to have deficits in 
different neurocognitive domains and, among them, 
memory, attention, and executive functions would be the 
most compromised (7, 8). In addition, schizophrenia 
patients often experience low level of performances and 
a reduced ability to live independently despite the 
remission of the acute symptomatology (9-11), with a 
negative impact on the social and occupational 













Of note, social cognition, defined as the mental 
operations underlying social interactions (10), has been 
recently interpreted as a mediator between 
neurocognition and functional outcome in schizophrenia 
(13). Furthermore, in light of the importance of cognitive 
impairment in affecting schizophrenia outcome, the 
interest in cognitive functioning has raised in the last 
twenty years (14,15) and cognitive impairment has been 
considered as an important pharmacological target for 
the development of new drugs in schizophrenia, having 
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With regard to clinical symptoms, the available data 
show that cognitive impairment seems to be more 
strongly associated with the severity of clinical 
negative symptoms respect to positive ones (17-19). In 
addition, higher estimated premorbid IQ, years of 
education and predominant disorganized symptoms 
seem to be important predictors of poor neurocognitive 
performances (20-22).  
In schizophrenia patients, gender differences have been 
found in verbal learning and recall: a poorer 
neurocognitive performance, particularly in verbal 
memory, has been associated with male gender (20). 
Furthermore, altered neurocognitive functioning in 
several domains has been reported in schizophrenia 
patients with lifetime cannabis abuse (3, 23 and 24). In 
contrast, a meta-analysis found superior neurocognitive 
performances in cannabis-using patients compared to 
non-using ones (25). Moreover, a further study did not 
find significant differences on neurocognitive 
functioning or number of lost days of work between 
moderate/severe drug users and mild users or 
abstainers (26). Finally, alcohol abuse in schizophrenia 
is associated with more impaired functioning across 
many domains, including memory (27). It is currently 
debated if diagnostic subtypes are associated with 
severity of cognitive impairment. In two studies 
paranoid patients resulted to have better Verbal IQ, 
executive functioning and memory compared to 
undifferentiated ones (28-30), while another study 
showed that paranoid patients did not have higher 
intellectual functioning than those with a non-paranoid 
sub-type (31) . 
Duration of illness probably influences the severity and 
type of cognitive deficits: a study showed that chronic 
patients presented more severe cognitive impairment 
especially in verbal memory, visual memory and 
attention respect to recent-onset schizophrenia patients 
(22). Furthermore, a longer duration of illness was 
found to correlate with impairment on psychomotor 
processing speed, verbal fluency and verbal learning 
(32(. 
Duration of Untreated Psychosis (DUP)/ Untreated 
Illness (DUI) has been largely studied that an important 
factor in influencing cognitive abilities of 
schizophrenia patients. Longer DUP has been 
associated with deficits in Digit Symbol and 
Comprehension subtests (20), and, in first-episode 
schizophrenia, with deficits in verbal IQ, verbal 
learning, and verbal working memory (33). 
Some studies showed that early age at onset is 
associated with severe cognitive impairment in 
schizophrenia patients (34-36). A study found a 
relationship between early age at onset and poor 
performances on IQ, Digit Symbol Coding and Tower 
of London tests (37). These findings are in agreement 
with a study (38), which demonstrated that worse 
Tower of London Task scores may primarily 
characterize early-onset schizophrenia. In line with 
these results, late-onset schizophrenia could be 
associated with better socio-functional outcome and 
higher possibility to get married (39). 
On the basis of the mentioned data, the objectives of 
the present study are: 1) to assess the social cognition 
in a sample of stabilized schizophrenic outpatients and 
2) to find an eventual relation between clinical 
variables and general/social cognitive deficits in 
schizophrenic patients. 
 
Materials and Methods 
Thirty-five outpatients (twenty-nine males and six 
females) recruited from community services afferent to 
the Department of Psychiatry (University of Milan), 
with a diagnosis of schizophrenia according to DSM-5 
(40) and treated with an antipsychotic mono-therapy, 
were included into the study. 
Structured Clinical Interview for DSM –SCID-5-CV– 
(40), Global Assessment of Functioning – GAF (41), 
The Calgary Depression Scale for Schizophrenia - 
CDSS (42) and Positive and Negative Syndrome Scale 
- PANSS (43) were administered to the patients: those 
who showed a re-exacerbation of the disorder, as 
defined by a PANSS score > 60 (44), were excluded. 
Other exclusion criteria were comorbidity with mental 
retardation or other neurological conditions involving 
Central Nervous System (e.g. cerebral tumors), 
presence of a comorbid Axis I disorder (except 
substance or alcohol misuse), comorbidity with 
medical diseases (e.g. hypothyroidism) or metabolic 
disorders causing psychiatric symptoms, pregnancy and 
breastfeeding. 
The design of the study was naturalistic and cross-
sectional. General cognitive functioning and social 
cognitive functioning was assessed by this way: 
General Cognitive assessment  
General cognitive assessment was obtained using the 
Brief Assessment of Cognition in Schizophrenia - 
BACS (45, 46) that is a neuropsychological battery 
which includes Verbal Fluency, Token Motor Task, 
Symbol Coding, Tower of London Test, Verbal 
Memory (list learning) and Working memory (digit 
sequencing). 
Verbal Fluency: patients have to say that many words 
as possible from a category in a given time (in our case 
60 seconds). This category can be semantic such as 
furniture or fruits, or phonemic, such as words that 
begin with letter b. 
Token Motor Task: patients are given 100 plastic 
tokens and asked to place them into a container as 
quickly as possible for 60 seconds. 
Symbol Coding: it consists of nine digit-symbol pairs 
followed by a list of digits. Under each digit the patient 
should write down the corresponding symbol as fast as 
possible. 
Tower of London: it consists of two boards with pegs 
and several beads with different colors. The rater uses 
the board in a variety of ways to test problem solving 
skills. 
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Verbal Memory (list learning): patients are presented 
with 15 words and then asked to recall as many as 
possible. 
Working Memory (digit sequencing): patients are 
presented with clusters of numbers of increasing 
length. 
Social cognition battery 
In light of an overlapped cognitive impairment between 
schizophrenia and fronto-temporal dementia (47), 
social cognition was assessed using a 5-test battery 
sensitive in detecting executive and social cognitive 
impairment in early stages of the behavioral variant of 
Frontotemporal dementia (48).  
1 .Multiple Errands Test for Use in Hospital Settings 
(MET-HV): the test requires subjects to carry out a 
number of tasks simulating “real life” situations where 
minor inconveniences can take place (49). 
2 .The Hotel Task: the task comprises six activities that 
would plausibly need to be completed in the course of 
running a hotel (50) . 
3. Iowa gambling task: this test mimics real-life 
personal decision-making activities that include reward 
and punishment (51). 
4. Reading the Mind in the Eyes: participants are 
required to choose between four options (adjectives) 
that best describes what the individual in the presented 
photo are thinking or feeling (52, 53). 
5. Faux Pas Test: participants have to find something 
inappropriate in tales that they have to read and that 
may contain a social “faux pas” (a violation of 
accepted social norms) (54) . 
Statistical analysis  
Descriptive statistics were performed in order to 
evaluate general and social cognition in the total 
sample. Binary logistic models were then performed. In 
these analyses, the failure in a single test was 
considered that the dependent variable, while age, age 
at onset, duration of illness, DUI, Calgary scores, GAF 
scores and PANSS scores were the covariates. Χ2 tests 
were used to compare dichotomous variables (gender, 
diagnostic subtypes, type of abuse) and cognitive test 




Descriptive statistics of the total sample are reported in 
table 1. In our sample patients showed impairment in 
different several domains. The worst performances 
resulted in Faux Pas Test (failure in 90.3% of patients), 
Token Motor Task (failure in 82.9% of patients) and 
Symbol Coding (failure in 80.0% of patients). 
In table 2 the mean test scores are reported together 
with the percentage of failing patients. 
The goodness-of-fit test results (Hosmer and 
Lemeshow Test: χ2=8.83, df =7, p=0.265) showed that 
the model including continuous variables/scale scores 
as possible predictors of Tower of London failure was 
adequate, allowing for a correct classification of 77.1% 
of the cases.  
 
Table1. Demographic and Clinical Variables of the Clinically Stabilized Patients with Schizophrenia 
Variables N=35 
Gender Male 29 (82.9) 
Female 6 (17.1) 
Age 41.40 + 10.22 
Age at onset 20.94 + 3.70 
Prevalent Symptoms 
 
Psychotic 11 (31.4) 
Negative 15 (42.9) 
Disorganization 9 (25.7) 
Abuse before the onset  No 13 (37.1) 
Yes 22 (62.9) 
Duration of illness 20.46 + 11.29 
Type of abuse  None 13 (37.1) 
Alcohol 5 (14.3) 
Cannabis 11 (31.4) 
Cocaine 4 (11.4) 
Heroin 2 (5.7) 
Duration of untreated illness 2.80 + 4.78 
Treatment Quetiapine 3 (8.6) 
Olanzapine 5 (14.3) 
Risperidone 8 (22.9) 
Aripiprazole 5 (14.3) 
Zuclopenthixol 7 (20.0) 
Haloperidol 5 (14.3) 
Paliperidone 2 (5.7) 
PANSS total score 48.06 + 3.92 
CDSS 4.74 + 3.88 
GAF 43.34 + 11.79 
Note: Standard deviations for continuous variables and percentages for dichotomous ones are reported into brackets 
PANSS: Positive and Negative Syndrome Scale 
CDSS: The Calgary Depression Scale for Schizophrenia 
GAF: Global Assessment of Functioning 
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% of Failure 
BACS 
Verbal Memory 
vn > 33.01 
21 57 35.69 ± 8.477 60.0 
Working Memory 
vn > 14.93 
3.25 26.25 16.87 ± 5.339 51.4 
Token Task 
vn > 68.77 
25 90 61.15 ± 16.126 82.9 
Symbol Coding Task 
vn > 40.49 
15 63 38.56 ± 10.858 80.0 
Verbal Fluency 
vn > 31.68 
16.3 58.5 34.04 ± 9.587 68.6 
Tower of London 
vn > 12.37 
0 20 12.79 ± 4.010 68.6 
SOCIAL COGNITION 
MET      
Tasks attempted 4 12 10.07 ± 2.288 56.7 
Task failures 0 8 1.93 ± 2.288 56.7 
Inefficiencies 0 3 1.47 ± 0.776 56.7 
Rule breaks 0 2 0.63 ± 0.615 0.0 
Interpretation failure 0 4 0.63 ± 0.999 40.0 
Total failures 0 11 4.67 ± 3.294 30.0 
HOTEL      
Tasks attempted 0 5 3.17 ± 1.315 53.3 
Tasks correct 0 5 3.17 ± 1.315 53.3 
Time deviation (sec) 0 720 277.93 ± 209.415 24.1 
Button pressing 0 2 1.3 ± 0.915 40.0 
Opening deviation 0 4 2.67 ± 1,826  
Closing deviation 0 4 2.17 ± 1,913  
Garage time deviation 0 8 4.83 ± 3.534 50.0 
IOWA GAMBLING TASK -42 52 -1.1 ± 21.806 58.1 
THEORY OF MIND TESTS 
THE EYES TEST 10 25 19.68 ± 4.482 35.5 
FAUX PAS TEST 0 20 12.52 ± 3.846 90.3 
BACS: Brief Assessment of Cognition in Schizophrenia 
HOTEL: The Hotel Task 
MET: Multiple Errands Test 
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Table3. Summary of the Statistics for the Best-Fit Logistic Regression Model Applied 
Clinical Variables/ Scale Scores B S.E. Wald df p Exp (B) 
Age 0.013 0.055 0.058 1 0.809 -1.013 
Age at onset -3.54 0.170 4.321 1 0.038 0.702 
DUI 0.056 0.117 0.230 1 0.632 1.058 
CDSS scores -0.236 0.143 2.718 1 0.099 0.790 
GAF scores 0.037 0.045 0.658 1 0.417 1.037 
PANSS scores 0.285 0.187 2.331 1 0.127 1.33 
 
In this analysis the dependent variable was the Tower of London success 
B=coefficient; S.E.= standard error of B; Wald=Wald statistics; df= degree of freedom; p=significance; Exp (B)=odds 
ratio.  
CDSS= Calgary Depression Scale for Schizophrenia 
GAF= Global Assessment of Functioning 
PANSS= Positive and Negative Syndrome Scale 
Omnibus Test of Model Coefficients: χ2=13.22, df=6, p=0.04 


































* Statistics:  
χ
2
=4.80, p=0.05, Phi=0.40 
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Figure2. Substance Abuse and Differences in Verbal Fluency Performances 
 
 
In addition, the model was overall significant 
(Omnibus test: χ2=13.22, df=6, p=0.04). An early age 
at onset was found to be associated with BACS Tower 
of London failure (OR=0.702, p=0.038). No further 
statistically significant associations were found (table 
3). With regard to dichotomous variables, female 
schizophrenia patients showed more frequently failures 
in MET (total errors: χ2=4.80, p=0.05, Phi=0.40) 
(Figure 1) and in the HOTEL task (number of 
performed activities: χ2=5.25, p=0.04, Phi=0.42; 
number of correctly performed activities: χ2=5.25, 
p=0.04, Phi=0.42). In addition, cannabis abusers 
showed more frequently deficits on verbal fluency (χ2= 
9.35, p=0.04, phi=0.52) (Figure 2) and executive 
functioning (Tower of London) (χ2= 11.67, p=0.02,  
phi=0.58) than alcohol/cocaine abusers. No further 
statistically significant associations were found. 
 
Discussion 
The first result of our study is that clinically stabilized 
schizophrenia patients present impairment in several 
cognitive domains particularly in language 
comprehension (Token Test), social sensitivity (Faux 
Pas Test) and memory (Digit Symbol Coding). This  
 
 
finding supports the statement that schizophrenia 
cognitive dysfunction is not only associated to acute re-
exacerbations, but it remains during the course of 
illness (55, 56). This is the reason why specific 
cognitive impairments have been recently proposed  
that neurocognitive markers of schizophrenic illness by 
international biological societies (57). 
The main result of the present paper is that an early age 
at onset is associated with severity of frontal cognitive  
 
 
impairment (Tower of London). Frontal cognitive 
disability limits rehabilitation programs and impairs 
quality of life so that our findings confirm the view that 
early-onset schizophrenia patients have very poor 
prognosis (58). It is actually debated if cognitive 
dysfunction can be associated with brain changes that 
have been found in early-onset schizophrenia patients 
by recent neuroimaging researches (59-63). 
Interestingly, our data show that frontal dysfunctions 
do not result to be associated with  
age so that they probably emerge in first years of 
illness and keep stable over time. On the basis of this 
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population) and secondary prevention programmes 
(early diagnosis) become preeminent to prevent or at 
least limit cognitive impairment and improve outcome 
of early-onset patients (64). 
The second result is a worse social cognition in female 
schizophrenia patients respect to male ones. This 
finding is surprising as female gender is generally 
considered having a better outcome than schizophrenic 
males especially in case of a long duration of illness 
(65, 66). Perhaps these are specific cognitive deficits of 
female gender as in our knowledge this is the first 
study assessing social cognition in a sample of 
schizophrenia patients by Torralva’s 
neuropsychological battery. The results suggest that 
endophenotypes in schizophrenia may be sex-specific 
(67). 
Finally, cannabis abuse appears to be associated with a 
more severe verbal/executive impairment in 
comparison with alcohol/cocaine abuse. It is 
traditionally stated that schizophrenic cannabis abusers 
show better neuropsychological performances than 
non-abusers in light of a baseline minor cognitive 
impairment (68). The discordant results of this paper 
can be explained by the long duration of illness of our  
sample: it can be hypothesized that cannabis-related 
cognitive impairment may be progressive during the 
course of schizophrenia, while cognitive impairment 
may be static in cocaine abusers (69). 
 
Limitation 
Limits of the present study have to be shortly 
described. First the sample size is small, but this is 
partially due to the selection of patients in mono-
therapies to limit the impact of medications on 
cognition. Second, possible confounding factors such 
as different antipsychotic mono-therapies might be 
biased the results, even though the available 
antipsychotics do not have a clear effect on cognition. 
Third gender imbalance in our sample might have 
influenced the study results. In contrast the naturalistic 
study design has the advantage to be more adherent 
with clinical practice. Studies with larger samples and 
possibly drug-naives could be useful to confirm the  
data of this article.  
 
Conclusion 
Stabilized schizophrenia patients show marked 
cognitive impairment especially regarding memory and 
social sensitivity. Early age at onset is associated with 
even a more compromised neuropsychological state 
with worse outcomes on executive functioning. Female 
gender appears to be associated with a poorer social 
cognitive functioning and cannabis abuse with 
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